Kidney Cancer

Cabometyx had better progression-free survival rates than Sutent (sunitinib) for certain patients with renal cell carcinoma.

Progression-free survival (PFS) was not significantly improved with the combination of dalantercept plus Inlyta (axitinib) in patients with advanced renal cell carcinoma (RCC) compared with placebo, according to the results from the phase 2 DART trial.

Bavencio and Inlyta together produced a promising response for some patients with renal cell carcinoma.

There are 16 known genes that cause kidney cancer and at least 13 different types of inherited kidney cancer, emphasizing the need to understand genetic differences between these disease.

James Brugarolas, M.D., Ph.D., discusses the importance of spotting the difference between a metastatic kidney cancer lesion and a separate lung cancer. The difference can save patients' lives.

David McDermott, M.D. discusses new advances made to treat kidney cancer.

An independent data monitoring committee recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC) be stopped, but Argos Therapeutics explained that they will keep the trial open.

A randomized trial showed that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) has some promise for the frontline treatment of some patients with RCC.

A recent study found that patients with metastatic renal cell carcinoma may see extended response even after stopping immunotherapy treatment.

Patients with metastatic kidney cancer may see a decreased efficacy of their immunotherapy regimen if they recently took antibiotics.

Sutent treatment breaks seem to have no effect on clinical efficacy for patients with renal cell carcinoma.

CURE spoke with Neeraj Agarwal, M.D., about the underreporting and underemphasizing of toxicities with PD-1 inhibitors in renal cell carcinoma.

Vaccines are currently being tested in their potential to improve immunotherapy responses for patients with renal cell carcinoma.

Elizabeth Plimack, M.D., discusses an update on the CheckMate-025 trial, comparing Opdivo to Afinitor in patients with metastatic renal cell carcinoma.

David F. McDermott, M.D., is optimistic about combination regimens shaping the treatment landscape for renal cell carcinoma.

After the approvals of agents in the second-line setting, researchers are now turning to improving the frontline treatment of kidney cancer.

Will the newly approved kidney cancer treatments eventually end up in the frontline setting? Expert Chung-Han (Joe) Lee, M.D., weighs in.

Obesity can negatively affect cancer treatment outcomes, trigger disease recurrence and shorten longevity. Organized weight loss programs and exercise can help patients protect themselves.

Immunotherapy combinations are on the horizon for the treatment of renal cell carcinoma, Robert J. Motzer, M.D., says.

Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.

A panel of experts recently discussed the evolving field of immunotherapy for solid tumor types.

TKIs will continue to shape the landscape of kidney cancer treatment, Robert A. Figlin, M.D., F.A.C.P., says.

Cabometyx was proved to be superior to Sutent, reducing rates of disease progression or death for patients with metastatic RCC, according to a recent trial.

In a recent phase 2 trial, Cabometyx showed longer progression-free survival than Sutent in patients with metastatic kidney cancer.

After going through the "Dark Ages," we're approaching the "Golden Age" of kidney cancer care, with more options available than ever, says James Hsieh.

There have been some exciting advances in using immunotherapy to treat GU malignancies such as kidney and bladder cancer. CURE sat down with Elizabeth Plimack, M.D. to discuss them.

The treatment landscape for advanced kidney cancer has changed dramatically over the past few years, with several targeted drugs and an immunotherapy approved by the FDA.

Ten years ago, patients with advanced RCC had very few treatment options, yet today, there are multiple therapeutic strategies and more in the pipeline for this not-very-common tumor type, writes our editor-in-chief, Debu Tripathy.

While many new treatment options have been introduced for kidney cancer in recent years, the question of how to sequence them is still being debated.